Onco Actu du 15 novembre 2016

	3.1 Tabac
If smoking doesn’t kill, Mike Pence, neither does the plague [The Conversation] US Vice President elect Mike Pence (who has been the recipient of funding from Big Tobacco) once famously wrote: Time for a quick reality check. Despite the hysteria from the political class and the media, smoking doesn’t kill. In fact two out of every three smokers does [sic] not die from smoking-related illness and nine out of ten smokers do not contract lung cancer.
	3.7 Alcool
10 things you might not know about alcohol and cancer [Cancer Research UK] From working out what on earth a unit of alcohol is, to clearing up some myths about popular hangover cures, here’s what you need to know about alcohol and cancer.
	4.12 Biopsies liquides
Lymphoma shares secrets in its circulating tumor DNA [Stanford] The researchers used an enhanced version of a technology they developed called CAPP-Seq to predict which seemingly successfully treated patients would relapse, or whose indolent lymphomas were becoming aggressive, months before any clinical signs occurred.
	4.2 Dép., diag. & prono. - Génome
Inside the drive to collect DNA from 1 million veterans and revolutionize medicine [STAT] The Department of Veterans Affairs is gathering blood from 1 million veterans and sequencing their DNA. At the same time, computer scientists are creating a database that combines those genetic sequences with electronic medical records and other information about veterans’ health.
	5. Traitements
NCRI 2016: Could exciting new treatments to block cancer evolution halt drug resistance? [Institute of Cancer Research] Scientists are increasingly excited about a new area of research that aims to slow or even halt the evolution of resistance. Among a number of potential leads, research to target a family of molecules called APOBEC proteins is causing a stir.
Targeting the cell’s master controller: Myc [Cancer Research UK] If researchers are successful in developing a drug that breaks up Aurora-A and N-Myc’s friendship, without blocking Aurora-A’s normal job in cell division, it could be turned into a potential treatment for neuroblastoma and medulloblastoma.
A Hot Souvenir From Cuba for Some Americans: Cancer Vaccine [NY Times] The trial could take years, but American cancer patients are not waiting. Over the past couple of years, dozens have slipped into Havana and smuggled vials of the vaccine in refrigerated lunchboxes back to the United States, sometimes not even telling their doctors.
	5.10 Traitements - Essais
New drug beats standard therapy in advanced kidney cancer [Dana-Farber Cancer Institute] Individuals who received the drug, cabozantinib, had a longer time to progression – the interval before their cancer worsened – than those taking sunitinib (Sutent), the drug that has been the standard initial treatment for metastatic kidney cancer for the past decade.
	5.12.1 Immunothérapies - partenariats
Pfizer lines up three experimental I/O meds for NCI research tie-up [FierceBiotech] The co-op deal, financial details of which were not published, will see the two assess Pfizer’s ($PFE) OX40 agonist, its utomilumab and the German Merck-partnered avelumab both alone and in various combos with other meds, including chemo, radiation therapy and standard meds.
Pfizer to Collaborate with National Cancer Institute to Study Three Immunotherapy Agents Targeting Multiple Cancers [Pfizer] Cooperative Research and Development Agreement (CRADA) assesses OX40 agonist, utomilumab and avelumab immuno-oncology assets alone and in various combinations.
Roche launches imCORE, a global network of cancer immunotherapy centers of excellence [Roche] Roche will invest up to 100 million Swiss Francs to support basic and clinical research collaborations related to cancer immunotherapy.
Roche launches cancer immunotherapy research network [Reuters] The research network of 21 academic centers around the world is intended to support basic and clinical research collaboration to advance the science of cancer immunotherapy, the Basel-based drugmaker said on Tuesday.
	5.12.3 Immunothérapies-combinaisons
Immune checkpoint inhibitors shrink tumors in 26 to 38 percent of metastatic bladder cancer patients [MD Anderson Cancer Center] In the randomized phase I/II clinical trial known as CheckMate 032, patients who progress after platinum-based chemotherapy received either the anti-PD1 inhibitor nivolumab, or one of two combinations of nivolumab plus the CTLA4 inhibitor ipilimumab.
	5.2 Pharma
The Novartis house that Vasella built gets extreme makeover [Reuters] Novartis pharmaceuticals unit, which received GSK's cancer drugs in the 2014 swap, also this year underwent a separate reorganization, in part to direct its focus to oncology.
	5.3 Traitements - FDA, EMA, NICE...
Revising the guideline on first-in-human clinical trials [EMA] Changes are open for comments until end of February 2017.
	5.3.4 Traitements - AMM (FDA, EMA)
EMA Recommends Nine Drugs for Approval [RAPS] In addition, EMA recommended extensions of indications for Novartis’ Arzerra (ofatumumab), Genzyme’s Caprelsa (vandetanib.
	5.4 Traitements - Economie
Cancer drug pricing in Europe [Healthcare Economist] With the exception of Germany, most countries had a national and/or regional drug budget. Germany is also unique in that only Germany and the UK allow for free pricing, whereas other countries use reference pricing or price negotiation.
NICE rebuffs Celgene's Revlimid in second-line multiple myeloma [FiercePharma] The draft rejection follows a similar decision for Amgen’s Kyprolis last week. NICE decided Kyprolis was not cost-effective for patients who’ve had one prior therapy.
	5.7 SABCS
Puma Biotechnology Announces Presentations of Investigational Data at the San Antonio Breast Cancer Symposium (SABCS) [Puma] Its lead drug candidate PB272 (neratinib) will be featured in 11 poster presentations at the 2016 San Antonio Breast Cancer Symposium (SABCS), December 6 - 10, 2016, in San Antonio, Texas.
	5.9 AACR
Blueprint Medicines to Present Preliminary Data from Ongoing Phase 1 Clinical Trials for BLU-285 and BLU-554 at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics [PRNewswire] Preliminary Data for BLU-285 in Gastrointestinal Stromal Tumors (GIST) Accepted for Late-Breaking Oral Presentation.
	6.10 Politiques
'Relentless drive' call for early cancer diagnosis [BBC News] Tom Crosby, medical director of the Wales Cancer Network, made his comment as the Welsh Government launched its refreshed cancer delivery plan.
	6.11 Patients
‘It seemed like I had climbed Mount Everest’: A rough year after daring cancer surgery [STAT] This is one in a series of occasional updates on the lives of people featured by STAT during our first year.
‘Colontown’ gives cancer patients an edge in finding new treatments [STAT] Patients without time to wait for a big taxpayer-powered breakthrough are putting their trust in the latter. They’re trying to craft their own individual moonshots with scraps of data they’ve collected from other patients in Colontown, a members-only Facebook page for colorectal cancer patients.
	6.5 Médecines alternatives
Quackademic medicine at Memorial Sloan-Kettering Cancer Center [Respectful Insolence] Sadly, SIO and the integrative medicine service at MSKCC are just two examples of all too many. All over the US—the world, even—once rigorously science-based institutions are embracing pseudoscience. Unfortunately, the reasons they give are the same all over the world and just as deluded.
	6.6 Publications
Two Harvard-led groups pull well-cited cancer papers for duplication [Retraction Watch] Both papers — which are more than a decade old — were pulled in The Journal of Clinical Investigation on November 1 by their respective corresponding authors.
A Painful (but True-to-life) Look at Data Availability and Reuse [The Scholarly Kitchen] Data availability and re-usability starts with best practices in collecting and storing data in the first place. The exasperatingly funny video below shows what happens when those best practices are ignored, something that’s much more prevalent than it should be.